Aquestive Therapeutics (AQST) PT Raised to $10 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts AQST Hot Sheet
Price: $3.88 +2.92%
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Oppenheimer analyst Francois Brisebois raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $10.00 (from $9.50) while maintaining a Outperform rating.
You May Also Be Interested In
- Aquestive Therapeutics Inc. (AQST) Misses Q3 EPS by 6c
- UBS Downgrades Alphatec Holdings (ATEC) to Neutral
- Vertex (VRTX) PT Raised to $619 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
